4.6 Article

Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk

Journal

MOVEMENT DISORDERS
Volume 37, Issue 6, Pages 1202-1210

Publisher

WILEY
DOI: 10.1002/mds.28987

Keywords

Parkinson's disease; GBA; lysosomal genes; mutation burden

Funding

  1. PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale) [2017228L3J]
  2. Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy
  3. Fondazione Grigioni per il Morbo di Parkinson
  4. Intramural Research Programs of the National Institute on Aging (NIA)
  5. National Institutes of Health (National Institute of Neurological Disorders and Stroke) [R01NS096740]

Ask authors/readers for more resources

The study evaluated the contribution of rare variants in genes responsible for lysosomal storage disorders (LSDs) to the risk of Parkinson's disease (PD) associated with the GBA gene. It found a significantly increased burden of deleterious variants in LSD genes in PD patients and identified the second variation in GBA and variants in genes causing mucopolysaccharidoses as the strongest modifiers of GBA penetrance.
Background To date, variants in the GBA gene represent the most frequent large-effect genetic factor associated with Parkinson's disease (PD). However, the reason why individuals with the same GBA variant may or may not develop neurodegeneration and PD is still unclear. Objectives Therefore, we evaluated the contribution of rare variants in genes responsible for lysosomal storage disorders (LSDs) to GBA-PD risk, comparing the burden of deleterious variants in LSD genes in PD patients versus asymptomatic subjects, all carriers of deleterious variants in GBA. Methods We used a custom next-generation sequencing panel, including 50 LSD genes, to screen 305 patients and 207 controls (discovery cohort). Replication and meta-analysis were performed in two replication cohorts of GBA-variant carriers, of 250 patients and 287 controls, for whom exome or genome data were available. Results Statistical analysis in the discovery cohort revealed a significantly increased burden of deleterious variants in LSD genes in patients (P = 0.0029). Moreover, our analyses evidenced that the two strongest modifiers of GBA penetrance are a second variation in GBA (5.6% vs. 1.4%, P = 0.023) and variants in genes causing mucopolysaccharidoses (6.9% vs. 1%, P = 0.0020). These results were confirmed in the meta-analysis, where we observed pooled odds ratios of 1.42 (95% confidence interval [CI] = 1.10-1.83, P = 0.0063), 4.36 (95% CI = 2.02-9.45, P = 0.00019), and 1.83 (95% CI = 1.04-3.22, P = 0.038) for variants in LSD genes, GBA, and mucopolysaccharidosis genes, respectively. Conclusion The identification of genetic lesions in lysosomal genes increasing PD risk may have important implications in terms of patient stratification for future therapeutic trials. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available